EA201590449A1 - Перорально вводимая лекарственная композиция - Google Patents

Перорально вводимая лекарственная композиция

Info

Publication number
EA201590449A1
EA201590449A1 EA201590449A EA201590449A EA201590449A1 EA 201590449 A1 EA201590449 A1 EA 201590449A1 EA 201590449 A EA201590449 A EA 201590449A EA 201590449 A EA201590449 A EA 201590449A EA 201590449 A1 EA201590449 A1 EA 201590449A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
release portion
portion containing
Prior art date
Application number
EA201590449A
Other languages
English (en)
Inventor
Юуки Цуцуи
Хироясу Тойота
Тадаси Хакомори
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201590449A1 publication Critical patent/EA201590449A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Для предоставления в области медицины одного состава, содержащего часть с модифицированным высвобождением, содержащую мирабегрон или его фармацевтически приемлемую соль, и часть с немедленным высвобождением, содержащую солифенацин или его фармацевтически приемлемую соль, представлен (1) один состав, обладающий скоростями растворения обоих лекарственных средств, сходными со скоростями растворения в современных составах лекарственных средств, и (2) один состав, обладающий максимальными процентами растворения обоих лекарственных средств 90% или более и обладающий биодоступностью, эквивалентной биодоступности в современных составах отдельных лекарственных средств. Кроме того, для предоставления одного состава представлен (3) один состав, обладающий хорошей эффективностью производства, в соответствии с чем уменьшены трудности в изготовлении таблеток, и обладающий хорошей стабильностью при хранении, в соответствии с чем уменьшено окрашивание части с немедленным высвобождением. Фармацевтическая композиция для перорального введения по настоящему изобретению содержит (1) часть с модифицированным высвобождением, содержащую мирабегрон или его фармацевтически приемлемую соль, и (2) часть с немедленным высвобождением, содержащую солифенацин или его фармацевтически приемлемую соль и стеарат кальция.
EA201590449A 2012-08-31 2013-08-30 Перорально вводимая лекарственная композиция EA201590449A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012191833 2012-08-31
PCT/JP2013/073351 WO2014034860A1 (ja) 2012-08-31 2013-08-30 経口投与用医薬組成物

Publications (1)

Publication Number Publication Date
EA201590449A1 true EA201590449A1 (ru) 2015-06-30

Family

ID=50183665

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590449A EA201590449A1 (ru) 2012-08-31 2013-08-30 Перорально вводимая лекарственная композиция

Country Status (17)

Country Link
US (1) US20150306090A1 (ru)
EP (1) EP2891493A4 (ru)
JP (1) JPWO2014034860A1 (ru)
KR (1) KR20150045500A (ru)
CN (1) CN104602693A (ru)
AU (1) AU2013309922A1 (ru)
BR (1) BR112015004244A2 (ru)
CA (1) CA2883270A1 (ru)
EA (1) EA201590449A1 (ru)
HK (1) HK1208801A1 (ru)
IL (1) IL237423A0 (ru)
MX (1) MX2015002633A (ru)
PH (1) PH12015500313A1 (ru)
SG (1) SG11201501415RA (ru)
TW (1) TW201424772A (ru)
WO (1) WO2014034860A1 (ru)
ZA (1) ZA201501977B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
AU2015358378A1 (en) 2014-12-03 2017-06-29 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
WO2017186598A1 (en) * 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3448367A1 (en) 2016-04-25 2019-03-06 Synthon BV Tablets comprising mirabegron and solifenacin
CN107397733B (zh) * 2016-05-20 2020-02-07 山东威智百科药业有限公司 一种米拉贝隆缓释片及其制备方法
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
CN106361715A (zh) * 2016-09-02 2017-02-01 迪沙药业集团有限公司 米拉贝隆组合物
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법
KR20170088783A (ko) * 2017-07-07 2017-08-02 지엘팜텍주식회사 미라베그론의 습식과립 조성물
WO2019013583A2 (ko) * 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
US10478399B2 (en) * 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
KR102371567B1 (ko) * 2018-04-06 2022-03-07 한미약품 주식회사 미라베그론이 함유된 방출 제어 약학적 조성물
WO2020097328A1 (en) * 2018-11-07 2020-05-14 Velicept Therapeutics, Inc Fixed dose pharmaceutical compositions for treating overactive bladder and related conditions
KR102062791B1 (ko) * 2019-02-26 2020-01-06 신일제약 주식회사 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제
US20210353546A1 (en) * 2020-05-12 2021-11-18 Jubilant Pharma Holdings Inc. Dual release pharmaceutical compositions comprising the combination of a beta-3 adrenoreceptor agonist and a muscarinic receptor antagonist
EP4159199A1 (en) 2021-09-29 2023-04-05 Lotus Pharmaceutical Co., Ltd. Combined formulation of mirabegron and solifenacin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
PT1019039E (pt) * 1997-10-03 2002-04-29 Warner Lambert Co Comprimido de nitroglicerina comprimida e metodo para o seu fabrico
BR9804500B1 (pt) 1997-10-17 2010-06-15 derivado de amida, referida composição farmacêutica e agente terapêutico.
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2503570C (en) 2002-11-07 2011-04-19 Yamanouchi Pharmaceutical Co., Ltd. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US20100240697A1 (en) * 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
MY160652A (en) * 2009-02-04 2017-03-15 Astellas Pharma Inc Pharmaceutical composition for oral administration
MX353105B (es) * 2010-08-03 2017-12-19 Velicept Therapeutics Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva.
TWI612975B (zh) * 2012-03-02 2018-02-01 安斯泰來製藥股份有限公司 速崩散性錠劑

Also Published As

Publication number Publication date
CN104602693A (zh) 2015-05-06
WO2014034860A1 (ja) 2014-03-06
PH12015500313A1 (en) 2015-04-20
IL237423A0 (en) 2015-04-30
KR20150045500A (ko) 2015-04-28
AU2013309922A1 (en) 2015-04-09
EP2891493A4 (en) 2016-05-18
JPWO2014034860A1 (ja) 2016-08-08
MX2015002633A (es) 2015-06-24
SG11201501415RA (en) 2015-05-28
BR112015004244A2 (pt) 2017-07-04
TW201424772A (zh) 2014-07-01
HK1208801A1 (en) 2016-03-18
EP2891493A1 (en) 2015-07-08
CA2883270A1 (en) 2014-03-06
ZA201501977B (en) 2016-07-27
US20150306090A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
MY160652A (en) Pharmaceutical composition for oral administration
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MY165149A (en) Use of binders for manufacturing storage stable formulations
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
NZ631100A (en) Soft chewable pharmaceutical products
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
PH12015500823A1 (en) Modified release formulations for oprozomib
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
JP2018039810A5 (ru)
CY1118181T1 (el) Αναβραζοντα δισκια για χρηση σε εισπνοες
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства
MX2014005960A (es) Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2.
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
NZ596881A (en) Phentermine liquid dosage form
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
EA201991359A1 (ru) Фармацевтические лекарственные формы